Salivary gland mucinous adenocarcinoma

Summary

Salivary gland mucinous adenocarcinoma (MONDO:0850273) is a disease. A subtype of salivary gland carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	salivary gland mucinous adenocarcinoma
Mondo ID	MONDO:0850273
DOID	DOID:0080800
NCIT	C62193
UMLS	C1882973
MedGen	364330
GARD	0028070
Is cancer (heuristic)	no

Disease family

This is a subtype of salivary gland carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › oral cavity cancer › salivary gland cancer › salivary gland carcinoma › salivary gland mucinous adenocarcinoma

Related subtypes (12): salivary gland adenoid cystic carcinoma, major salivary gland carcinoma, salivary gland basal cell adenocarcinoma, salivary gland carcinoma ex pleomorphic adenoma, salivary gland large cell carcinoma, salivary gland small cell carcinoma, salivary gland epithelial myoepithelial carcinoma, salivary gland mucoepidermoid carcinoma, salivary gland squamous cell carcinoma, salivary duct carcinoma, minor salivary gland carcinoma, mammary analog secretory carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.